Wells Fargo & Company Issues Pessimistic Forecast for Septerna (NASDAQ:SEPN) Stock Price

Septerna (NASDAQ:SEPN) had its price target dropped by Wells Fargo & Company from $14.00 to $11.00 in a report issued on Friday, Marketbeat reports. The firm presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price would indicate a potential upside of 112.36% from the stock’s previous close.

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price target on shares of Septerna in a research note on Tuesday, February 11th.

Septerna Stock Down 5.8 %

Septerna stock traded down $0.32 during mid-day trading on Friday, hitting $5.18. The stock had a trading volume of 19,683 shares, compared to its average volume of 457,900. The firm’s 50-day moving average is $9.18. Septerna has a 12 month low of $4.17 and a 12 month high of $28.99.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.05. The company had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.13 million. As a group, sell-side analysts expect that Septerna will post -7.11 EPS for the current year.

Insider Activity at Septerna

In other Septerna news, CFO Gil M. Labrucherie bought 5,000 shares of the company’s stock in a transaction on Friday, February 21st. The stock was acquired at an average price of $5.85 per share, for a total transaction of $29,250.00. Following the completion of the transaction, the chief financial officer now directly owns 30,000 shares of the company’s stock, valued at approximately $175,500. This represents a 20.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Alan Ezekowitz bought 41,355 shares of the business’s stock in a transaction on Thursday, March 6th. The shares were acquired at an average cost of $6.00 per share, for a total transaction of $248,130.00. Following the transaction, the director now directly owns 104,101 shares in the company, valued at approximately $624,606. This trade represents a 65.91 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 74,346 shares of company stock worth $439,670.

Institutional Investors Weigh In On Septerna

Hedge funds and other institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. purchased a new position in shares of Septerna during the 4th quarter valued at approximately $160,205,000. TRV GP V LLC acquired a new stake in shares of Septerna in the fourth quarter worth approximately $142,337,000. TRV GP VI LLC acquired a new stake in Septerna during the 4th quarter worth $72,191,000. Samsara BioCapital LLC acquired a new stake in shares of Septerna in the fourth quarter valued at about $63,399,000. Finally, Driehaus Capital Management LLC purchased a new position in shares of Septerna in the fourth quarter worth about $59,301,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.